Bimolecular fluorescence complementary system based on red fluorescent protein mScarlet3 as well as construction method and application of bimolecular fluorescence complementary system
Through a two-molecular fluorescence complementary system based on the red fluorescent protein mScarlet3, the problems of false positives, weak brightness and slow maturity time in the prior art were solved, and the detection effect of high signal-to-noise ratio and fast observation of protein interactions was achieved.
Patent Information
- Application Number
- CN202410968080.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-18
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2044-07-18
AI Technical Summary
The existing bimolecular fluorescence complementary system has problems such as false positives, weak brightness and slow maturity time when detecting protein-protein interactions, which affects the signal-to-noise ratio and observation efficiency.
A two-molecular fluorescent complementary system based on the red fluorescent protein mScarlet3 was developed. By dividing the mScarlet3 protein into two parts and expressing it separately, and reconstituting the fluorescent protein during protein interaction, gene cloning was performed using pcDNA3.1(+) vector. and polymerase chain reaction to construct vectors for expression to achieve strong signal and low background fluorescence imaging.
It improves the signal-to-noise ratio, reduces the background signal, shortens the observation time, and enhances the detection sensitivity and accuracy of protein interactions.
Smart Images

Figure CN119023634A_ABST
Abstract
Description
Technical Field
[0001] The present application belongs to the technical field of fluorescence imaging of protein interactions in living cells, and specifically relates to the development and application of a bimolecular fluorescence complementation system. Background Art
[0002] Protein-protein interactions and protein-nucleic acid interactions are the basis of many intracellular biological processes. Studying the interactions between these biomacromolecules not only helps to understand the cellular physiological mechanisms at the molecular level, but is also an effective means to discover many new drug targets. Over the past few decades, many technologies have been developed to study protein-protein interactions, such as Fluorescence Resonance Energy Transfer, Co-Immunoprecipitation, and Yeast Two-Hybrid Assay. They each have different advantages, but also have some limitations. Among many technologies, bimolecular fluorescence complementation (BiFC) is favored by researchers as a method that can directly observe protein-protein interactions in situ under physiological conditions.
[0003] Fluorescent proteins such as green fluorescent protein (GFP) are composed of a barrel-shaped structure composed of β-pleated sheets and a chromophore composed of several amino acids in the center of the barrel. The bimolecular fluorescence complementation technology involves the splitting and reorganization of fluorescent proteins: the fluorescent protein is divided into the N-terminus and the C-terminus, and then fused with two test proteins for expression. If there is indeed an interaction between the two test proteins, the N-terminus and C-terminus of the fluorescent protein covalently linked to them will also be recombined into a complete fluorescent protein structure due to spatial proximity and emit fluorescence. The advantages of bimolecular fluorescence complementation technology are its simple operation, high sensitivity, and ability to detect weak interactions and transient interactions. Over the past decade, more and more fluorescent proteins have been used in bimolecular fluorescence complementation, which not only enriches the spectral coverage of the technology, but also improves the performance of the system.
[0004] Among red fluorescent proteins, bimolecular fluorescence complementation systems based on mRFP1-Q66T, mCherry, and mScarlet I have been developed. However, due to the performance defects of each of these fluorescent proteins, the bimolecular fluorescence complementation systems developed by them will also show deficiencies in some aspects. For example, earlier developed RFPs such as mRFP1-Q66T and mCherry have problems such as low quantum yield, photochromism or residual dimerization tendency, which may reduce the signal-to-noise ratio of the detection to a certain extent. The first-generation protein of the mScarlet series has high inherent brightness, no photochromism, and is a completely monomeric RFP, but it also has the problem of relatively slow maturation time, which may cause the subcellular localization of fluorescence observed in bimolecular fluorescence complementation to be inconsistent with the actual interaction of the protein. The variant of the first-generation mScarlet, mScarlet I, has been greatly improved in maturation time and degree of maturation, but the inherent brightness is lower than that of the first-generation mScarlet protein. Therefore, this application is proposed for the problems of false positives, weak brightness, slow maturation time, etc. in the existing bimolecular fluorescence complementation system. Summary of the invention
[0005] The first objective of the present application is to provide a bimolecular fluorescence complementation system based on the red fluorescent protein mScarlet3, which overcomes the problems of false positive, weak brightness and slow maturation time existing in the prior art.
[0006] In order to achieve the aforementioned invention objectives, the technical solutions adopted in this application include:
[0007] A bimolecular fluorescence complementation system based on red fluorescent protein mScarlet3 comprises a first vector and a second vector; the red fluorescent protein mScarlet3 is a protein composed of 229 amino acids, and the amino acid sequence of the red fluorescent protein mScarlet3 is shown in sequence SEQ ID NO.1; the first vector is a vector comprising a gene sequence for expressing a first protein fragment, and the second vector is a vector comprising a gene sequence for expressing a second protein fragment, and when the first protein fragment and the second protein fragment are close to each other, they can be reconstructed to form the red fluorescent protein mScarlet3; wherein: the first protein fragment is a protein fragment composed of amino acids at positions 1 to n of the red fluorescent protein mScarlet3, and the second protein fragment is a protein fragment composed of amino acids at positions (n+1) to 229 of the red fluorescent protein mScarlet3; and n is 154 or 169.
[0008] In some embodiments, when n is 154, the first protein fragment is the mSc154N protein fragment, and the second protein fragment is the mSc155C protein fragment; the gene sequence for expressing mSc154N comprises the gene sequence SEQ ID NO.3 and the gene sequence for expressing the mSc155C protein fragment comprises the gene sequence SEQ ID NO.4.
[0009] In other embodiments, when n is 169, the first protein fragment is the mSc169N protein fragment, and the second protein fragment is the mSc170C protein fragment; the gene sequence used to express the mSc169N protein fragment includes the gene sequence SEQ ID NO.5 and the gene sequence used to express the mSc170C protein fragment includes the gene sequence SEQ ID NO.6.
[0010] Furthermore, the first vector further includes a first gene sequence, the first gene sequence is used to express a first protein to be tested, the first vector is used to express a first fusion protein, and the first fusion protein is a fusion protein of the first protein to be tested and a first protein fragment. The second vector further includes a second gene sequence, the second gene sequence is used to express a second protein to be tested, the second vector is used to express a second fusion protein, and the second fusion protein is a fusion protein of the second protein and a second protein fragment.
[0011] The second object of the present application is to provide a method for constructing a bimolecular fluorescence complementation system based on the red fluorescent protein mScarlet3, comprising the following steps:
[0012] S1: cloning the gene sequence of the red fluorescent protein mScarlet3 into the first eukaryotic expression vector to synthesize a gene vector containing mScarlet3;
[0013] S2: Using the gene vector containing mScarlet3 as a template, a gene sequence for expressing the first protein fragment and a gene sequence for expressing the second protein fragment are obtained by polymerase chain reaction;
[0014] S3: using a recombinase to insert a gene sequence for expressing the first protein fragment into a second eukaryotic expression vector to form a first vector; using a recombinase to insert a gene sequence for expressing the second protein fragment into a third eukaryotic expression vector to form a second vector;
[0015] The red fluorescent protein mScarlet3 is composed of 229 amino acids, and its amino acid sequence is shown in the sequence SEQ ID NO1, and the gene sequence is shown in the sequence SEQ ID NO2; when the first protein fragment and the second protein fragment are close to each other, they can be reconstructed to form the red fluorescent protein mScarlet3; wherein: the first protein fragment is a protein fragment composed of amino acids from position 1 to position n of the red fluorescent protein mScarlet3, and the second protein fragment is a protein fragment composed of amino acids from position (n+1) to position 229 of the red fluorescent protein mScarlet3; n is 154 or 169.
[0016] Furthermore, the first eukaryotic expression vector includes one of pcDNA3.1(+) vector, pUC57, and pUC19; the second eukaryotic expression vector includes one of pcDNA3.1(+) vector, pUC57, and pUC19; and the third eukaryotic expression vector includes one of pcDNA3.1(+) vector, pUC57, and pUC19.
[0017] In some embodiments, the first eukaryotic expression vector is a pcDNA3.1(+) vector, the gene vector containing mScarlet3 is pcDNA3.1-mScarlet3; the gene sequence for expressing mSc154N is the gene sequence SEQ ID NO.3 and the gene sequence for expressing the mSc155C protein fragment is the gene sequence SEQ ID NO.4; in step S2:
[0018] When the gene sequence SEQ ID NO.3 was obtained by polymerase chain reaction using pcDNA3.1-mScarlet3 as a template,
[0019] The upstream primers are:
[0020] 5'-ACCCAAGCTGGCTAGCCACCATGGATAGCACCGAGGCAGT-3'
[0021] The downstream primers are:
[0022] 5'-ACGGGCCCTCTAGACTCGAGTCAGTCCTCGGGGTACAACC-3';
[0023] When the gene sequence SEQ ID NO.4 was obtained by polymerase chain reaction using pcDNA3.1-mScarlet3 as a template,
[0024] The upstream primers are:
[0025] 5'-CCAAGCTGGCTAGCCACCATGGTCGTGCTGAAGGGCG-3'
[0026] The downstream primers are:
[0027] 5'-GGCCCTCTAGACTCGAGTCAGGAGCCACCGGAGCCGCCGG-3'.
[0028] In other embodiments, the first eukaryotic expression vector is a pcDNA3.1(+) vector, the gene vector containing mScarlet3 is pcDNA3.1-mScarlet3; the gene sequence for expressing mSc169N is the gene sequence SEQ ID NO.5 and the gene sequence for expressing the mSc170C protein fragment is the gene sequence SEQ ID NO.6; in step S2:
[0029] When the gene sequence SEQ ID NO.5 was obtained by polymerase chain reaction using pcDNA3.1-mScarlet3 as a template,
[0030] The upstream primers are:
[0031] 5'-CCAAGCTGGCTAGCCACCatggatagcaccgaggcagt-3'
[0032] The downstream primers are:
[0033] 5'-ACGGGCCCTCTAGACTCGAGTCAgtccttcaggcgcag-3'
[0034] When the gene sequence SEQ ID NO.6 was obtained by polymerase chain reaction using pcDNA3.1-mScarlet3 as a template,
[0035] The upstream primers are:
[0036] 5'-CAAGCTGGCTAGCCACCatgggcggccgctacctg-3';
[0037] The downstream primers are:
[0038] 5'-CCTCTAGACTCGAGTCAggagccaccggagccgccg-3'.
[0039] The third object of the present invention is to provide the application of the bimolecular fluorescence complementation system based on the red fluorescent protein mScarlet3 in the imaging of protein-protein interactions in the first object.
[0040] Further, the following steps are included:
[0041] Step A1: cloning the gene sequences of the first protein to be tested and the second protein to be tested into the first vector and the second vector, respectively, to obtain the first protein to be tested-first vector plasmid and the second protein to be tested-second vector plasmid;
[0042] Step A2: using a transfection reagent to co-transfect the constructed test protein-first vector plasmid and the test protein-second vector plasmid into the cells to be tested;
[0043] Step A3: After a period of incubation, perform fluorescence microscopy imaging.
[0044] Compared with the prior art, the present invention applies mScarlet3 fluorescent protein to bimolecular fluorescence complementation, and selects a fluorescent protein splitting site with a strong signal and extremely low background signal. Compared with the previous bimolecular fluorescence complementation system based on red fluorescent protein, the red fluorescent protein used in this system has the characteristics of low dimerization, high intrinsic brightness, and short maturation time. Therefore, the system developed by it has the characteristics of low background, high signal-to-noise ratio, and short observation time. Based on these advantages, this system can be used to further screen other protein-protein interactions. BRIEF DESCRIPTION OF THE DRAWINGS
[0045] Figure 1 pcDNA3.1-mScarlet3 plasmid map.
[0046] Figure 2 Plasmid maps of the first vector and the second vector.
[0047] Figure 3 Plasmid maps of EGFP-mSc154N, mSc155C-EGFP, EGFP-mSc169N, and mSc170C-EGFP.
[0048] Figure 4 (A): Fluorescence emitted by cells 16 hours after co-transfection of EGFP-mSc154N and mSc155C-EGFP; (B): Fluorescence emitted by cells 16 hours after co-transfection of EGFP-mSc169N and mSc170C-EGFP.
[0049] Figure 5bJun-mSc154N, mSc155C-bFos, mSc155C-bFosdZIP plasmid maps.
[0050] Figure 6 (A): Fluorescence emitted by cells 16 hours after co-transfection of bJun-mSc154N and mSc155C-bFos; (B): Fluorescence emitted by cells 16 hours after co-transfection of bJun-mSc154N and mSc155C-bFosdZIP.
[0051] Fig. 7 Plasmid maps of ORC1-mSc169N and mSc170C-HMGA1a.
[0052] Figure 8 Fluorescence of cells 16 hours after co-transfection of ORC1-mSc169N and mSc170C-HMGA1a. DETAILED DESCRIPTION
[0053] The present application is further described below with reference to embodiments, but is not limited thereto.
[0054] Unless otherwise specified, the materials and reagents used in the following examples can be obtained from commercial sources. The terms "first", "second" and the like in this application are used to distinguish different objects, rather than to describe a specific order.
[0055] The present application provides a bimolecular fluorescence complementation system based on the red fluorescent protein mScarlet3, including a first vector and a second vector; the red fluorescent protein mScarlet3 is a protein composed of 229 amino acids, and the amino acid sequence of the red fluorescent protein mScarlet3 is shown in the sequence SEQ ID NO. 1. The first vector is a vector containing a gene sequence for expressing a first protein fragment, and the second vector is a vector containing a gene sequence for expressing a second protein fragment. When the first protein fragment and the second protein fragment are close to each other, they can be reconstructed to form the red fluorescent protein mScarlet3.
[0056] The present application discloses two sets of bimolecular fluorescence complementation systems based on the red fluorescent protein mScarlet3. The two sets of bimolecular fluorescence complementation systems and their construction methods and applications are respectively introduced below.
[0057] Embodiment 1:
[0058] The first bimolecular fluorescence complementation system comprises a first vector ( Figure 2A ) and a second vector comprising the sequence SEQ ID NO4 ( Figure 2B ). Specifically, the first protein fragment is a protein fragment consisting of amino acids 1 to 154 of the red fluorescent protein mScarlet3, named mSc154N; the second protein fragment is a protein fragment consisting of amino acids 155 to 229 of the red fluorescent protein mScarlet3, named mSc155C.
[0059] The construction method of the first bimolecular fluorescence complementation system is as follows:
[0060] Step S1: synthesize a gene vector containing mScarlet3. The gene sequence of mScarlet3 is shown in SEQ ID NO.2. The gene sequence of mScarlet3 is cloned into the pcDNA3.1(+) vector and named pcDNA3.1-mScarlet3. The map of the synthesized vector is shown in Figure 1 shown.
[0061] Step S2: PCR is performed using pcDNA3.1-mScarlet3 as a template to amplify the sequence SEQ ID NO.3. It should be known to those skilled in the art that appropriate upstream and downstream primers can be designed according to actual conditions. It should be noted that when designing primers, homologous sequences that can be recognized by the recombinase in step S3 need to be added to the primers. In this embodiment, the upstream primer used to amplify the sequence SEQ ID NO.3 is:
[0062] 5'-ACCCAAGCTGGCTAGCCACCATGGATAGCACCGAGGCAGT-3'
[0063] The downstream primers are:
[0064] 5'-ACGGGCCCTCTAGACTCGAGTCAGTCCTCGGGGTACAACC-3'
[0065] Step S3: Use a recombinase to insert the sequence SEQ ID NO.3 for expressing mSc154N into the pcDNA3.1 vector to form a first vector containing the sequence SEQ ID NO.3. The plasmid map is shown in Figure 2A shown.
[0066] Those skilled in the art should be aware that the recombinase is not limited to a form, such as the recombinase and the buffer being separated or being a premixed solution. In this embodiment, the "Novorec Plus One Step Cloning Kit" recombinant cloning kit is used. In addition, the "Vazyme ClonExpress Ultra One Step Cloning Kit", "pEASY-Basic Seamless Cloning and Assembly Kit" and the like can also achieve the functions of this embodiment.
[0067] Those skilled in the art should also know that the pcDNA3.1 vector fragment can be obtained by a variety of methods. In this embodiment, the pcDNA3.1-mScarlet3 was used as a template to amplify and recover the pcDNA3.1 vector fragment. The upstream primers used were:
[0068] 5'-CTCGAGTCTAGAGGGCCCGTTTAAACCCGC-3'
[0069] The downstream primers are:
[0070] 5'-CATGGTGGCTAGCCAGCTTGGG-3'
[0071] Similarly, when PCR is performed using pcDNA3.1-mScarlet3 as a template to amplify the sequence SEQ ID NO.4, appropriate upstream and downstream primers can be designed according to the actual situation. It should be noted that when designing primers, homologous sequences that can be recognized by the recombinase need to be added to the primers. In this embodiment, the upstream primer used to amplify the sequence SEQ ID NO.4 is:
[0072] 5'-CCAAGCTGGCTAGCCACCATGGTCGTGCTGAAGGGCG-3'
[0073] The downstream primers are:
[0074] 5'-GGCCCTCTAGACTCGAGTCAGGAGCCACCGGAGCCGCCGG-3'
[0075] The upstream primers used to amplify the pcDNA3.1 vector fragment using pcDNA3.1-mScarlet3 as a template are:
[0076] 5'-CTCGAGTCTAGAGGGCCCGTTTAAACCCGC-3'
[0077] The downstream primers are:
[0078] 5'-CATGGTGGCTAGCCAGCTTGGG-3'
[0079] The above primers were used to amplify and recover the pcDNA3.1 vector fragment. Then, the sequence SEQ ID NO.4 for expressing mSc154N was inserted into the pcDNA3.1 vector using a recombinase to form a second vector containing the sequence SEQ ID NO.4. The plasmid map is shown in Figure 2B shown.
[0080] The first vector and the second vector constructed above were transformed into Escherichia coli respectively, and after the sequences were verified by sequencing, the endotoxin-free plasmid was extracted using an endotoxin-free plasmid mini-preparation kit.
[0081] Application of the first bimolecular fluorescence complementation system:
[0082] Step A1: clone the gene sequences of the first test protein and the second test protein into the first vector and the second vector respectively to obtain the first test protein-first vector plasmid and the second test protein-second vector plasmid.
[0083] Specifically include:
[0084] After constructing the first vector containing the sequence SEQ ID NO.3 and the second vector containing the sequence SEQ ID NO.4, PCR is used to amplify the DNA sequences of the first test protein and the second test protein from the ready-made plasmid or cDNA library. It should be known to those skilled in the art that the orientation between the first test protein and the second test protein and mSc154N or mSc155C can be adjusted according to the actual situation.
[0085] The present application does not limit the first protein to be tested and the second protein to be tested. In some embodiments, the first protein to be tested and the second protein to be tested may be known interacting proteins, such as the first protein to be tested is FKBP protein, and the second protein to be tested is FRB protein; or, the first protein to be tested is Bak protein, and the second protein to be tested is Bcl-XL protein; or, the first protein to be tested is bJun protein, and the second protein to be tested is bFos protein, etc., and the system of the present application is used to determine whether there is a specific protein-protein interaction in the cell. In other embodiments, the first protein to be tested and the second protein to be tested may be proteins whose interactions are unknown, and the system provided by the present application may be used to determine whether there is an interaction between the two proteins as the research object.
[0086] In this embodiment, the enhanced green fluorescent protein (Enhanced Green Fluorescent Protein) that can form a homodimer is taken as an example, hereinafter referred to as EGFP. That is to say, in this embodiment, the first protein to be tested and the second protein to be tested are both EGFP. Using the pX458 plasmid as a template, primers for amplifying the EGFP fragment are designed and synthesized. It should be noted that when designing primers, it is necessary to add a linker sequence between EGFP and the mSc154N protein fragment or between EGFP and the mSc155C protein fragment, and it is necessary to add a homologous sequence that can be recognized by the recombinase to the primer. The linker amino acid sequence connecting EGFP and the mSc154N protein fragment is such as the sequence SEQ ID NO.7, and the gene sequence is such as the sequence SEQ ID NO.8.
[0087] When EGFP was linked to the N-terminus of the mSc154N protein fragment, the upstream primer used to amplify EGFP was:
[0088] 5'-CCCAAGCTGGCTAGCCACCATGGTGAGCAAGGGCGAGGAG-3'
[0089] The downstream primers are:
[0090] 5'-ACTGCCTCCACCTCCGCTACCTCCACCGCCCTTGTACAGCTCGTCCATGCCG-3'
[0091] When the first vector sequence is amplified using the first vector containing the sequence SEQ ID NO.3 as a template, the upstream primer is:
[0092] 5'-TAGCGGAGGTGGAGGCAGTATGGATAGCACCGAGGCAG-3'
[0093] The downstream primers are:
[0094] 5'-CATGGTGGCTAGCCAGCTTGGG-3'
[0095] The above primers were used to amplify and recover the first vector fragment, and then the EGFP was inserted into the first vector containing the sequence SEQ ID NO.3 using a recombinase to form pcDNA3.1-EGFP-154N. The plasmid map is shown in Figure 3A shown.
[0096] The amino acid sequence of the linker connecting EGFP and the mSc155C protein fragment is shown in SEQ ID NO.9, and the gene sequence is shown in SEQ ID NO.10.
[0097] When EGFP was linked to the C-terminus of the mSc155C protein fragment, the upstream primer used to amplify EGFP was:
[0098] 5'-GGCTCTGGCTCAGGCAGTATGGTGAGCAAGGGCGAGGAG-3'
[0099] The downstream primers are:
[0100] 5'-TTTAAACGGGCCCTCTAGACTCGAGTCACTTGTACAGCTCGTCC-3'
[0101] When the second vector sequence containing SEQ ID NO.4 is amplified using the second vector as a template, the upstream primer is:
[0102] 5'-GGCTCTGGCTCAGGCAGTATGGTGAGCAAGGGCGAGGAG-3'
[0103] The downstream primers are:
[0104] 5'-CATGGTGGCTAGCCAGCTTGGG-3'
[0105] The second vector fragment was amplified and recovered using the above primers, and then EGFP was inserted into the second vector containing the sequence SEQ ID NO.4 using a recombinase to form pcDNA3.1-155C-EGFP. The plasmid map is shown in Figure 3B shown.
[0106] Step A2: The pcDNA3.1-EGFP-154N and pcDNA3.1-155C-EGFP constructed above were transformed into Escherichia coli. After the sequence was verified to be correct by sequencing, the endotoxin-free plasmid was extracted using an endotoxin-free plasmid mini-preparation kit.
[0107] Lipofectamine 3000 was used to transfect the two plasmids into the cells to be tested at a ratio of 1:1.
[0108] Step A3: After 12 to 24 hours, observe the cells to be tested using a fluorescence microscope. Figure 4 As shown in A (the cells to be detected are HEK293T cells), the transfected cells exhibit bright red fluorescence.
[0109] In another embodiment: bJun protein is used as the first protein to be detected, and bFos protein is used as the second protein to be detected.
[0110] 1. pcDNA3.1(+)-lifeact-mScarlet3 was synthesized by Sangon Biotechnology Co., Ltd.
[0111] The bJun and bFos sequences were obtained by PCR from existing plasmids in the laboratory. It should be noted that when designing primers, a linker sequence needs to be added between bJun or bFos and mSc154N or mSc155C, and a homologous sequence that can be recognized by the recombinase needs to be added to the primers.
[0112] Using the first vector or the second vector as a template, the first vector sequence or the second vector sequence is obtained by PCR amplification and recovery. Using the Novorec PCR one-step directional cloning kit, bJun is inserted into the first vector to obtain the plasmid bJun-mSc154N, such as Figure 5A shown.
[0113] The same method was used to clone bFos into the second vector to obtain plasmid bFos-mSc155C, such as Figure 5B shown.
[0114] Using bFos-mSc155C as a template, bFos lacking the ZIP domain that interacts with bJun was obtained by PCR and named bFosdZIP. It was cloned together with mSc155C into the pcDNA3.1 vector to obtain the plasmid bFosdZIP-mSc155C. Figure 5C shown.
[0115] 2. Transient Transfection of HEK293T Cells
[0116] The human kidney epithelial cell line HEK293T was maintained by the inventor's laboratory.
[0117] Lipofectamine 3000 liposome transfection reagent was used to co-transfect bJun-mSc154N and bFos-mSc155C, bJun-mSc154N and bFosdZIP-mSc155C (as a negative control) into HEK293T cells at a 1:1 ratio.
[0118] 16 hours after transfection, cells were observed using a fluorescence microscope and the fluorescence signals were recorded.
[0119] 3. Observation results
[0120] like Figure 6 As shown in A, cells transfected with bJun-mSc154N and bFos-mSc155C emit bright red fluorescence. Figure 6 As shown in B, the fluorescence brightness of the negative control, i.e., cells transfected with bJun-mSc154N and bFosdZIP-mSc155C, is much lower than that of cells transfected with bJun-mSc154N and bFos-mSc155C, indicating that there is an interaction between bJun and bFos, and this interaction depends on the ZIP sequence in bFos.
[0121] Embodiment 2:
[0122] The second bimolecular fluorescence complementation system comprises a first vector ( Figure 2C ) and a second vector comprising the sequence SEQ ID NO.6 ( Figure 2D ). Specifically, the first protein fragment is a protein fragment consisting of amino acids 1 to 169 of the red fluorescent protein mScarlet3, named mSc169N; the second protein fragment is a protein fragment consisting of amino acids 170 to 229 of the red fluorescent protein mScarlet3, named mSc170C.
[0123] The construction method of the second bimolecular fluorescence complementation system is as follows:
[0124] Step S1: As in Example 1, a gene vector containing mScarlet3 is synthesized. The gene sequence of mScarlet3 is shown in SEQ ID NO.2. The gene sequence of mScarlet3 is cloned into a pcDNA3.1(+) vector, named pcDNA3.1-mScarlet3. The synthesized vector map is shown in Figure 1 shown.
[0125] Step S2: PCR is performed using pcDNA3.1-mScarlet3 as a template to amplify the sequence SEQ ID NO.5. It should be known to those skilled in the art that appropriate upstream and downstream primers can be designed according to actual conditions. It should be noted that when designing primers, homologous sequences that can be recognized by the recombinase in step S3 need to be added to the primers. In this embodiment, the upstream primer used to amplify the sequence SEQ ID NO.5 is:
[0126] 5'-CCAAGCTGGCTAGCCACCATGGATAGCACCGAGGCAGT-3'
[0127] The downstream primers are:
[0128] 5'-ACGGGCCCTCTAGACTCGAGTCAGTCCTTCAGGCGCAG-3'
[0129] Step S3: Use a recombinase to insert the sequence SEQ ID NO.5 for expressing mSc169N into the pcDNA3.1 vector to form a first vector containing the sequence SEQ ID NO.5. The plasmid map is shown in Figure 2C shown.
[0130] Those skilled in the art should be aware that the recombinase is not limited to a form, such as the recombinase and the buffer being separated or being a premixed solution. In this embodiment, the "Novorec Plus One Step Cloning Kit" recombinant cloning kit is used. In addition, the "Vazyme ClonExpress Ultra One Step Cloning Kit", "pEASY-Basic Seamless Cloning and Assembly Kit" and the like can also achieve the functions of this embodiment.
[0131] Those skilled in the art should also know that the pcDNA3.1 vector fragment can be obtained by a variety of methods. In this embodiment, the pcDNA3.1-mScarlet3 was used as a template to amplify and recover the pcDNA3.1 vector fragment. The upstream primers used were:
[0132] 5'-CTCGAGTCTAGAGGGCCCGTTTAAACCCGC-3'
[0133] The downstream primers are:
[0134] 5'-CATGGTGGCTAGCCAGCTTGGG-3'
[0135] Similarly, when PCR is performed using pcDNA3.1-mScarlet3 as a template to amplify the sequence SEQ ID NO.6, appropriate upstream and downstream primers can be designed according to the actual situation. It should be noted that when designing primers, homologous sequences that can be recognized by the recombinase need to be added to the primers. In this embodiment, the upstream primer used to amplify the sequence SEQ ID NO.6 is:
[0136] 5'-CAAGCTGGCTAGCCACCATGGGCGGCCCGCTACCTG-3'
[0137] The downstream primers are:
[0138] 5'-CCTCTAGACTCGAGTCAGGAGCCACCGGAGCCGCCG-3'
[0139] The upstream primers used to amplify the pcDNA3.1 vector fragment using pcDNA3.1-mScarlet3 as a template are:
[0140] 5'-CTCGAGTCTAGAGGGCCCGTTTAAACCCGC-3'
[0141] The downstream primers are:
[0142] 5'-catGGTGGCTAGCCAGCTTGGG-3'
[0143] The above primers were used to amplify and recover the pcDNA3.1 vector fragment. Then, the sequence SEQ ID NO.6 for expressing mSc170C was inserted into the pcDNA3.1 vector using a recombinase to form a second vector containing the sequence SEQ ID NO.6. The plasmid map is shown in Figure 2D shown.
[0144] The first vector and the second vector constructed above were transformed into Escherichia coli respectively, and after the sequences were verified by sequencing, the endotoxin-free plasmid was extracted using an endotoxin-free plasmid mini-preparation kit.
[0145] The second application of bimolecular fluorescence complementation system:
[0146] Step A1: clone the gene sequences of the first test protein and the second test protein into the first vector and the second vector respectively to obtain the first test protein-first vector plasmid and the second test protein-second vector plasmid.
[0147] Specifically include:
[0148] After constructing the first vector containing the sequence SEQ ID NO.5 and the second vector containing the sequence SEQ ID NO.6, PCR is used to amplify the DNA sequences of the two test proteins from the ready-made plasmid or cDNA library. It should be known to those skilled in the art that the orientation between the first test protein and the second test protein and mSc154N or mSc155C can be adjusted according to the actual situation.
[0149] In this embodiment, EGFP that can form a homodimer is taken as an example. That is to say, in this embodiment, the first protein to be tested and the second protein to be tested are both EGFP. Using the pX458 plasmid as a template, primers for amplifying the EGFP fragment are designed and synthesized. It should be noted that when designing primers, a linker sequence needs to be added between EGFP and mSc169N or mSc170C, and a homologous sequence that can be recognized by the recombinase needs to be added to the primer. The linker amino acid sequence connecting EGFP and mSc169N is such as the sequence SEQ ID NO.7, and the gene sequence is such as the sequence SEQ ID NO.8.
[0150] When EGFP was linked to the N-terminus of mSc169N, the upstream primer used to amplify EGFP was:
[0151] 5'-CCCAAGCTGGCTAGCCACCatggtgagcaagggcgaggag-3'
[0152] The downstream primers are:
[0153] 5'-actgcctccacctccgctacctccaccgcccttgtacagctcgtccatgccg-3'
[0154] When the first vector containing the sequence SEQ ID NO.5 is used as a template to amplify the vector sequence, the upstream primer is:
[0155] 5'-tagcggaggtggaggcagtatggatagcaccgaggcag-3'
[0156] The downstream primers are:
[0157] 5'-CATGGTGGCTAGCCAGCTTGGG-3'
[0158] The above primers were used to amplify and recover the vector fragment, and then the EGFP was inserted into the first vector containing the sequence SEQ ID NO.5 using a recombinase to form pcDNA3.1-EGFP-169N. The plasmid map is shown in Figure 3C shown.
[0159] The amino acid sequence of the linker connecting EGFP and mSc170C is shown in SEQ ID NO.9, and the gene sequence is shown in SEQ ID NO.10.
[0160] When EGFP was linked to the C-terminus of mSc170C, the upstream primer used to amplify EGFP was:
[0161] 5'-GGCTCTGGCTCAGGCAGTATGGTGAGCAAGGGCGAGGAG-3'
[0162] The downstream primers are:
[0163] 5'-TTTAAACGGGCCCTCTAGACTCGAGTCACTTGTACAGCTCGTCC-3'
[0164] When the second vector containing the sequence SEQ ID NO.6 is used as a template to amplify the vector sequence, the upstream primer is:
[0165] 5'-CTCGAGTCTAGAGGGCCCGTTTAAACCCGC-3'
[0166] The downstream primers are:
[0167] 5'-ACTGCCTGAGCCAGAGCCGGAGCCACCGGAGCCGCCGG-3'
[0168] The above primers were used to amplify and recover the vector fragment, and then the EGFP was inserted into the second vector containing the sequence SEQ ID NO.6 using a recombinase to form pcDNA3.1-170C-EGFP. The plasmid map is shown in Figure 3D shown.
[0169] The pcDNA3.1-EGFP-169N and pcDNA3.1-170C-EGFP constructed above were transformed into Escherichia coli. After the sequences were verified by sequencing, the endotoxin-free plasmid was extracted using an endotoxin-free plasmid mini-preparation kit.
[0170] Lipofectamine 3000 was used to transfect the two plasmids into the cells to be tested at a ratio of 1:1.
[0171] After 12 to 24 hours, observe the cells under a fluorescence microscope. Figure 4 As shown in B, the transfected cells showed bright red fluorescence.
[0172] The second application of bimolecular fluorescence complementation system:
[0173] Taking the previously reported interacting proteins ORC1 and HMGA1a as an example, ORC1 protein was used as the first protein to be tested, and HMGA1a protein was used as the second protein to be tested.
[0174] 1. pcDNA3.1(+)-lifeact-mScarlet3 was synthesized by Sangon Biotechnology Co., Ltd.
[0175] 1.1 Using qPCR human reference total RNA (Takara) or mRNA extracted from cells as template, synthesize cDNA using the ReverTra Ace reverse transcription kit.
[0176] 1.2 The ORC1 and HMGA1a gene sequences were obtained by PCR using the synthesized cDNA as a template. It should be noted that when designing primers, a linker sequence needs to be added between ORC1 and mSc169N and between HMGA1a and mSc170C, and a homologous sequence that can be recognized by the recombinase needs to be added to the primers.
[0177] 1.3 Using the first vector or the second vector as a template, the first vector or the second vector sequence is obtained by PCR amplification and recovery.
[0178] 1.4 Use the Novorec PCR one-step directional cloning kit to insert ORC1 into the first vector to obtain plasmid ORC1-mSc169N, as shown in Fig. 7A shown.
[0179] 1.5 Use the same method to clone HMGA1a into the second vector to obtain plasmid mSc170C-HMGA1a, such as Figure 7B shown.
[0180] 2. Transient transfection of Hela cells
[0181] Hela cells were preserved by the inventor's laboratory.
[0182] 2.1 ORC1-mSc154N and mSc170C-HMGA1a were co-transfected into Hela cells at a 1:1 ratio using Lipofectamine 3000 liposome transfection reagent.
[0183] 2.2 16 hours after transfection, observe the cells using a fluorescence microscope and record the fluorescence signal.
[0184] 3. Observation results
[0185] like Figure 8 As shown, cells transfected with ORC1-mSc169N and mSc170C-HMGA1a emitted bright red fluorescence, indicating the interaction between ORC1 and HMGA1a.
[0186] SEQ ID NO.1
[0187] MDSTEAVIKEFMRFKVHMEGSMNGHEFEIEGEGEGRPYEGTQTAKLRVTKGGPLPFSWDI
[0188] LSPQFMYGSRAFTKHPADIPDYWKQSFPEGFKWERVMNFEDGGAVSVAQDTSLEDGTLIY
[0189] KVKLRGTNFPPDGPVMQKKTMGWEASTERLYPEDVVLKGDIKMALRLKDGGRYLADFKT
[0190] TYRAKKPVQMPGAFNIDRKLDITSHNEDYTVVEQYERSVARHSTGGSGGSSEQ ID NO.2
[0191] ATGGATAGCACCGAGGCAGTGATCAAGGAGTTCATGCGGTTCAAGGTGCACATGGAGG
[0192] GCTCCATGAACGGCCACGAGTTCGAGATCGAGGGCGAGGGCGAGGGCCGCCCCTACG
[0193] AGGGCACCCAGACCGCCAAGCTGAGGGTGACCAAGGGTGGCCCCCTGCCCTTCTCCTG
[0194] GGACATCCTGTCCCCTCAGTTCATGTACGGCTCCAGGGCCTTCACGAAGCACCCCGCCG
[0195] ACATCCCCGACTACTGGAAGCAGTCCTTCCCCGAGGGCTTCAAGTGGGAGCGCGTGAT
[0196] GAACTTCGAGGACGGCGGCGCCGTGTCCGTGGCCCAGGACACCTCCCTGGAGGACGGC
[0197] ACCCTGATCTACAAGGTGAAGCTCCGCGGCACCAACTTCCCTCCTGACGGCCCCGTAAT
[0198] GCAGAAGAAGACAATGGGCTGGGAAGCATCCACCGAGCGGTTGTACCCCGAGGACGT
[0199] CGTGCTGAAGGGCGACATTAAGATGGCCCTGCGCCTGAAGGACGGCGGCCGCTACCTG
[0200] GCGGACTTCAAGACCACCTACAGGGCCAAGAAGCCCGTGCAGATGCCCGGCGCCTTCA
[0201] ACATCGACCGCAAGTTGGACATCACATCCCACAACGAGGACTACACCGTGGTGGAACA
[0202] GTACGAACGCTCCGTGGCCCGCCACTCCACCGGCGGCTCCGGTGGCTCCSEQ ID NO.3
[0203] ATGGATAGCACCGAGGCAGTGATCAAGGAGTTCATGCGGTTCAAGGTGCACATGGAGG
[0204] GCTCCATGAACGGCCACGAGTTCGAGATCGAGGGCGAGGGCGAGGGCCGCCCCTACG
[0205] AGGGCACCCAGACCGCCAAGCTGAGGGTGACCAAGGGTGGCCCCCTGCCCTTCTCCTG
[0206] GGACATCCTGTCCCCTCAGTTCATGTACGGCTCCAGGGCCTTCACGAAGCACCCCGCCG
[0207] ACATCCCCGACTACTGGAAGCAGTCCTTCCCCGAGGGCTTCAAGTGGGAGCGCGTGAT
[0208] GAACTTCGAGGACGGCGGCGCCGTGTCCGTGGCCCAGGACACCTCCCTGGAGGACGGC
[0209] ACCCTGATCTACAAGGTGAAGCTCCGCGGCACCAACTTCCCTCCTGACGGCCCCGTAAT
[0210] GCAGAAGAAGACAATGGGCTGGGAAGCATCCACCGAGCGGTTGTACCCCGAGGACSEQ ID NO.4
[0211] ATGGTCGTGCTGAAGGGCGACATTAAGATGGCCCTGCGCCTGAAGGACGGCGGCCGCT
[0212] ACCTGGCGGACTTCAAGACCACCTACAGGGCCAAGAAGCCCGTGCAGATGCCCGGCGC
[0213] CTTCAACATCGACCGCAAGTTGGACATCACATCCCACAACGAGGACTACACCGTGGTG
[0214] GAACAGTACGAACGCTCCGTGGCCCGCCACTCCACCGGCGGCTCCGGTGGCTCCSEQ ID NO.5
[0215] ATGGATAGCACCGAGGCAGTGATCAAGGAGTTCATGCGGTTCAAGGTGCACATGGAGG
[0216] GCTCCATGAACGGCCACGAGTTCGAGATCGAGGGCGAGGGCGAGGGCCGCCCCTACG
[0217] AGGGCACCCAGACCGCCAAGCTGAGGGTGACCAAGGGTGGCCCCCTGCCCTTCTCCTG
[0218] GGACATCCTGTCCCCTCAGTTCATGTACGGCTCCAGGGCCTTCACGAAGCACCCCGCCG
[0219] ACATCCCCGACTACTGGAAGCAGTCCTTCCCCGAGGGCTTCAAGTGGGAGCGCGTGAT
[0220] GAACTTCGAGGACGGCGGCGCCGTGTCCGTGGCCCAGGACACCTCCCTGGAGGACGGC
[0221] ACCCTGATCTACAAGGTGAAGCTCCGCGGCACCAACTTCCCTCCTGACGGCCCCGTAAT
[0222] GCAGAAGAAGACAATGGGCTGGGAAGCATCCACCGAGCGGTTGTACCCCGAGGACGT
[0223] CGTGCTGAAGGGCGACATTAAGATGGCCCTGCGCCTGAAGGACSEQ ID NO.6
[0224] ATGGGCGGCCGCTACCTGGCGGACTTCAAGACCACCTACAGGGCCAAGAAGCCCGTGC
[0225] AGATGCCCGGCGCCTTCAACATCGACCGCAAGTTGGACATCACATCCCACAACGAGGA
[0226] CTACACCGTGGTGGAACAGTACGAACGCTCCGTGGCCCGCCACTCCACCGGCGGCTCC
[0227] GGTGGCTCC
[0228] SEQ ID NO.7
[0229] GGGGSGGGGS
[0230] SEQ ID NO.8
[0231] GGCGGTGGAGGTAGCGGAGGTGGAGGCAGTSEQ ID NO.9GSGSGSSEQ IDNO.10GGCTCTGGCTCAGGCAGT
Claims
1. A bimolecular fluorescence complementation system based on red fluorescent protein mScarlet3, characterized in that: The invention comprises a first vector and a second vector; the red fluorescent protein mScarlet3 is a protein composed of 229 amino acids, and the amino acid sequence of the red fluorescent protein mScarlet3 is shown in the sequence SEQ ID NO.1; the first vector is a vector comprising a gene sequence for expressing a first protein fragment, and the second vector is a vector comprising a gene sequence for expressing a second protein fragment, and when the first protein fragment and the second protein fragment are close to each other, they can be reconstructed to form the red fluorescent protein mScarlet3; wherein: the first protein fragment is a protein fragment composed of amino acids at positions 1 to n of the red fluorescent protein mScarlet3, and the second protein fragment is a protein fragment composed of amino acids at positions (n+1) to 229 of the red fluorescent protein mScarlet3; and n is 154 or 169.
2. The bimolecular fluorescence complementation system based on red fluorescent protein mScarlet3 according to claim 1, characterized in that: When n is 154, the first protein fragment is the mSc154N protein fragment, and the second protein fragment is the mSc155C protein fragment; the gene sequence for expressing mSc154N contains the gene sequence SEQ ID NO.3 and the gene sequence for expressing the mSc155C protein fragment contains the gene sequence SEQ ID NO.4; when n is 169, the first protein fragment is the mSc169N protein fragment, and the second protein fragment is the mSc170C protein fragment; the gene sequence for expressing the mSc169N protein fragment contains the gene sequence SEQ ID NO.5 and the gene sequence for expressing the mSc170C protein fragment contains the gene sequence SEQ ID NO.
6.
3. The bimolecular fluorescence complementation system based on red fluorescent protein mScarlet3 according to claim 1, characterized in that: The first vector further includes a first gene sequence, the first gene sequence is used to express a first protein to be tested, the first vector is used to express a first fusion protein, and the first fusion protein is a fusion protein of the first protein to be tested and the first protein fragment.
4. The bimolecular fluorescence complementation system based on red fluorescent protein mScarlet3 according to claim 1, characterized in that: The second vector further includes a second gene sequence, the second gene sequence is used to express a second protein to be tested, the second vector is used to express a second fusion protein, and the second fusion protein is a fusion protein of the second protein and the second protein fragment.
5. A method for constructing a bimolecular fluorescence complementation system based on red fluorescent protein mScarlet3, characterized in that: The steps include: S1: cloning the gene sequence of the red fluorescent protein mScarlet3 into the first eukaryotic expression vector to synthesize a gene vector containing mScarlet3; S2: using the gene vector containing mScarlet3 as a template, obtaining a gene sequence for expressing the first protein fragment and a gene sequence for expressing the second protein fragment by polymerase chain reaction; S3: using a recombinase to insert a gene sequence for expressing the first protein fragment into a second eukaryotic expression vector to form a first vector; using a recombinase to insert a gene sequence for expressing the second protein fragment into a third eukaryotic expression vector to form a second vector; The red fluorescent protein mScarlet3 is composed of 229 amino acids, and its amino acid sequence is shown in the sequence SEQ ID NO1, and the gene sequence is shown in the sequence SEQ ID NO2; when the first protein fragment and the second protein fragment are close to each other, they can be reconstructed to form the red fluorescent protein mScarlet3; wherein: the first protein fragment is a protein fragment composed of amino acids from position 1 to position n of the red fluorescent protein mScarlet3, and the second protein fragment is a protein fragment composed of amino acids from position (n+1) to position 229 of the red fluorescent protein mScarlet3; n is 154 or 169.
6. The method for constructing a bimolecular fluorescence complementation system based on red fluorescent protein mScarlet3 according to claim 5, characterized in that: The first eukaryotic expression vector includes one of pcDNA3.1(+) vector, pUC57, and pUC19; the second eukaryotic expression vector includes one of pcDNA3.1(+) vector, pUC57, and pUC19; and the third eukaryotic expression vector includes one of pcDNA3.1(+) vector, pUC57, and pUC19.
7. The method for constructing a bimolecular fluorescence complementation system based on red fluorescent protein mScarlet3 according to claim 5, characterized in that: The first eukaryotic expression vector is a pcDNA3.1(+) vector, the gene vector containing mScarlet3 is pcDNA3.1-mScarlet3; the gene sequence for expressing mSc154N is the gene sequence SEQ ID NO.3 and the gene sequence for expressing the mSc155C protein fragment is the gene sequence SEQ ID NO.4; in step S2: When the gene sequence SEQ ID NO.3 was obtained by polymerase chain reaction using pcDNA3.1-mScarlet3 as a template, The upstream primers are: 5'-ACCCAAGCTGGCTAGCCACCATGGATAGCACCGAGGCAGT-3' The downstream primers are: 5'-ACGGGCCCTCTAGACTCGAGTCAGTCCTCGGGGTACAACC-3'; When the gene sequence SEQ ID NO.4 was obtained by polymerase chain reaction using pcDNA3.1-mScarlet3 as a template, The upstream primers are: 5'-CCAAGCTGGCTAGCCACCATGGTCGTGCTGAAGGGCG-3' The downstream primers are: 5'-GGCCCTCTAGACTCGAGTCAGGAGCCACCGGAGCCGCCGG-3'.
8. The method for constructing a bimolecular fluorescence complementation system based on red fluorescent protein mScarlet3 according to claim 5, characterized in that: The first eukaryotic expression vector is a pcDNA3.1(+) vector, the gene vector containing mScarlet3 is pcDNA3.1-mScarlet3; the gene sequence for expressing mSc169N is the gene sequence SEQ ID NO.5 and the gene sequence for expressing the mSc170C protein fragment is the gene sequence SEQ ID NO.6; in step S2: When the gene sequence SEQ ID NO.5 was obtained by polymerase chain reaction using pcDNA3.1-mScarlet3 as a template, The upstream primers are: 5'-CCAAGCTGGCTAGCCACCatggatagcaccgaggcagt-3' The downstream primers are: 5'-ACGGGCCCTCTAGACTCGAGTCAgtccttcaggcgcag-3' When the gene sequence SEQ ID NO.6 was obtained by polymerase chain reaction using pcDNA3.1-mScarlet3 as a template, The upstream primers are: 5'-CAAGCTGGCTAGCCACCatgggcggccgctacctg-3'; The downstream primers are: 5'-CCTCTAGACTCGAGTCAggagccaccggagccgccg-3'.
9. An application of the bimolecular fluorescence complementation system based on red fluorescent protein mScarlet3 as claimed in any one of claims 1 to 4 in imaging protein-protein interactions.
10. The use according to claim 9, characterized in that The steps include: Step A1: cloning the gene sequences of the first protein to be tested and the second protein to be tested into the first vector and the second vector, respectively, to obtain the first protein to be tested-first vector plasmid and the second protein to be tested-second vector plasmid; Step A2: using a transfection reagent to co-transfect the constructed test protein-first vector plasmid and the test protein-second vector plasmid into the cells to be tested; Step A3: After a period of incubation, perform fluorescence microscopy imaging.
Citation Information
Patent Citations
Method for establishing bimolecular fluorescence complementary system based on red fluorescent protein in yeast
CN114839382A
A method of determining protein-protein interaction using viral vectors
KR101029972B1
Detection of protein interactions
US20070111192A1
Red fluorescent protein fragment having a self-assembly activity, method for preparing same, and method for analyzing protein-protein interactions using same
WO2012067402A2
